Literature DB >> 24104716

Growth of Scytalidium sp. in a counterfeit bevacizumab bottle.

Gerardo Garcia-Aguirre1, Virginia Vanzinni-Zago, Hugo Quiroz-Mercado.   

Abstract

After drawing a dose from an closed bevacizumab (Avastin) bottle, a fungus-like foreign body was observed inside. Samples from the vial were cultured in Sabouraud Emmons media. Growth of multiple light brown colonies with dark pigment was observed after 10 days. The species was identified as Scytalidium sp.Vial, analysis reported that the seal was lacking proper identification measures and that the label, batch number and expiry date did not correspond to a genuine product. Chemical analysis showed no protein, but 3% of polyethylene glycol, citrate and ethanol. Counterfeit bevacizumab is a real situation that poses a significant risk for ophthalmology and oncology patients. The medical community should be aware of this situation in order to enforce adequate preventive measures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24104716      PMCID: PMC3831773          DOI: 10.4103/0301-4738.119455

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  6 in total

1.  Ranibizumab for age-related macular degeneration.

Authors:  Jin-Wei Cheng; Rui-Li Wei
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

2.  Counterfeit bevacizumab and endophthalmitis.

Authors:  Xiaodong Sun; Xun Xu; Xi Zhang
Journal:  N Engl J Med       Date:  2011-07-28       Impact factor: 91.245

3.  An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab.

Authors:  Roger A Goldberg; Harry W Flynn; Ryan F Isom; Darlene Miller; Serafin Gonzalez
Journal:  Am J Ophthalmol       Date:  2012-02       Impact factor: 5.258

4.  Scytalidium keratitis: case report in a human eye.

Authors:  Qais A Farjo; Rand S Farjo; Ayad A Farjo
Journal:  Cornea       Date:  2006-12       Impact factor: 2.651

5.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

6.  Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan G Sanchez; Jans Fromow-Guerra; Lihteh Wu; Maria H Berrocal; Michel E Farah; Jose Cardillo; Francisco J Rodríguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-03       Impact factor: 3.117

  6 in total
  3 in total

Review 1.  After counterfeit Avastin®--what have we learned and what can be done?

Authors:  Tim K Mackey; Raphael Cuomo; Camille Guerra; Bryan A Liang
Journal:  Nat Rev Clin Oncol       Date:  2015-03-03       Impact factor: 66.675

2.  A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab.

Authors:  Morteza Entezari; Saeed Karimi; Hamid Ahmadieh; Amir Hossein Mahmoudi; Hamid Parhizgar; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-04       Impact factor: 3.117

3.  An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain.

Authors:  Raphael E Cuomo; Tim K Mackey
Journal:  BMJ Open       Date:  2014-12-02       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.